Maravai LifeSciences (MRVI) Misses Q3 EPS by 6c

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.05), $0.06 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $66.9 million versus the consensus estimate of $75.47 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Bristow Group to acquire Berry Aviation for $105 million